CTDNA MRD ASSESSMENT AND CLINICAL OUTCOMES IN HIGH-RISK ABC-DLBCL: UPDATED RESULTS FROM THE FIL_RI-CHOP TRIAL (SIE 2026) - Oct 6, 2026 - Abstract #C002; Pres time: Sep 21, 2026; 11:50 AM - 01:20 PM; Location: HALL 1; "The FIL_RI-CHOP trial evaluated R-CHOP plus ibrutinib (I) with I maintenance in young, untreated high-risk ABC-DLBCL, integrating molecular genotyping and ctDNA-based MRD analysis. The regimen was safe and highly effective with favorable PFS and no CNS relapses, despite the high-risk ABC-DLBCL population. ctDNA MRD retained independent prognostic value and should guide treatment stratification in future trials."
Circulating tumor DNA • Clinical • Clinical data • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Neutropenia
|
|
R. Moia1; A. Di Rocco2,3; N. Maher1; A. Chiappella4; A. Evangelista5; V. Tabanelli6; E. Ravano7; A. Tucci8; F. Cavallo9,10; F. Zaja11,12; B. Botto13; G. Loseto14; A. Merli15; A. Arcari16; M. Cimminiello17; A. Ferrari18; E. Pennese19; M. Zanni20; G. Gini21; U. Consoli22; A. Mele23; J. Olivieri24; M. Spina25; M. Tani26; A. Ferreri27; E. Derenzini28; A. Pinto29; S. Hohaus30; M. Coscia31,32; B. Puccini33; Marino D34; M. Almasri1; B. Al Deeban1; E. Genuardi9; F. Melle14; A. Dondi35; S. Ferrero9; U. Vitolo36; G. Gaidano1; M. Martelli2,3
|